| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445393 | European Journal of Cancer | 2013 | 11 Pages |
Abstract
ENMD-2076 has activity in platinum-resistant ovarian cancer, and observed toxicities were similar to other PO kinase inhibitors. Additional studies with ENMD-2076 are warranted, especially in combination with active chemotherapeutic agents in platinum-resistant patients. Further work to determine appropriate biomarkers for ENMD-2076 should be incorporated into new clinical studies.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ursula A. Matulonis, Julie Lee, Brian Lasonde, William P. Tew, Afra Yehwalashet, Daniela Matei, Kian Behbakht, Jill Grothusen, Gini Fleming, Nita K. Lee, Jamie Arnott, Mark R. Bray, Graham Fletcher, Richard D. Brokx, Vincent Castonguay, Helen Mackay,